Prosidyan announced FDA 510(k) clearance and commercial launch of FIBERGRAFT BG Matrix, a bone graft substitute for posterolateral spinal fusion.
This represents the third bioactive glass fiber-based product in the FIBERGRAFT line. Other formats include putty and morsels.
FIBERGRAFT products have been implanted in >9,000 recipients across the U.S. This is an increase from >7,000 at the end of 2Q17.
Source: Prosidyan
Prosidyan announced FDA 510(k) clearance and commercial launch of FIBERGRAFT BG Matrix, a bone graft substitute for posterolateral spinal fusion.
This represents the third bioactive glass fiber-based product in the FIBERGRAFT line. Other formats include putty...
Prosidyan announced FDA 510(k) clearance and commercial launch of FIBERGRAFT BG Matrix, a bone graft substitute for posterolateral spinal fusion.
This represents the third bioactive glass fiber-based product in the FIBERGRAFT line. Other formats include putty and morsels.
FIBERGRAFT products have been implanted in >9,000 recipients across the U.S. This is an increase from >7,000 at the end of 2Q17.
Source: Prosidyan
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE
ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
Copy to clipboard 
